RITALIN LA CII
Generic Name and Formulations:
Methylphenidate HCl 10mg, 20mg, 30mg, 40mg; ext-rel caps (one-half as immediate-release + one-half as enteric-coated, delayed-release beads).
Novartis Pharmaceuticals Corp
Indications for RITALIN LA:
Attention deficit hyperactivity disorder.
Adults and Children:
Swallow whole or sprinkle contents onto applesauce (swallow immediately); do not crush, chew, or divide beads. <6yrs: not recommended. ≥6yrs: initially 20mg once daily in the AM, may increase by 10mg weekly; max 60mg/day. Switching from methylphenidate immediate-release (IR) or SR: give total daily dose of IR or SR once daily in the AM.
Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family. During or within 14 days of MAOIs.
History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Avoid alcohol. Caution with pressor agents. May potentiate anticonvulsants (eg, phenobarbital, phenytoin, primidone), coumadin, TCAs, antipsychotics (eg, haloperidol); reduce dose of these and monitor. May antagonize antihypertensives. May be affected by antacids, acid suppressants. Risk of serotonin syndrome with serotonergic drugs.
Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache, rash; priapism, hypertension, tachycardia, visual disturbances.
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis